FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL								
OMB Number: 3235-028								
Estimated average burden								
hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* MUELLER PETER					<u>V</u>	2. Issuer Name and Ticker or Trading Symbol VERTEX PHARMACEUTICALS INC / MA [VRTX]							<u>/</u> (Cr	neck all a Dir	hip of Rep pplicable) ector icer (give		Person(s) to Is 10% C Other	
INCORP	C/O VERTEX PHARMACEUTICALS NCORPORATED					3. Date of Earliest Transaction (Month/Day/Year) 06/15/2011 4. If Amendment, Date of Original Filed (Month/Day/Year)									below) below) EVP, Global R&D, CSO			
130 WAVERLY ST (Street) CAMBRIDGE MA 02139				- 4. li	e) <mark>X</mark> Fo									ividual or Joint/Group Filing (Check Applical Form filed by One Reporting Person Form filed by More than One Reporting Person				
(City)	(S	tate)	(Zip)															
		Tab	le I - N	lon-Deriv	/ative	Sec	uriti	ies Ad	cquire	d, D	isposed c	f, or B	eneficia	lly Ow	ned			
1. Title of Security (Instr. 3)		2. Transaction Date (Month/Day/Year)		Execution Date,		3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 ar			Sec Ben Owi	mount of urities eficially ied Follow	F	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership			
							Code	v	Amount	(A) or (D)	Price	Trai	orted saction(s) tr. 3 and 4)			(Instr. 4)		
Common Stock 06/15/2			2011	11		М		2,500	A	\$10.41	L	136,235		D				
Common Stock 06/15/2			2011	11		S ⁽¹⁾		1,800	D	\$46.5(2)	(3)	134,435		D				
Common Stock 06/15/20			2011	11		S ⁽¹⁾		700	D	\$47.14 ⁽³)(4)	133,735		D				
Common Stock														4,495		I	401(k)	
		Т	able I								posed of converti			/ Own	ed	,		
Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	Execution Date,		4. Transaction Code (Instr. 8)				6. Date Exerc Expiration Da (Month/Day/Y		ate	7. Title a Amount Securitie Underlyi Derivativ (Instr. 3	of es ng ve Security	8. Price Derivat Securit (Instr. 5	ve deriv / Secu) Bene Owne Follo Repo	rities eficially ed owing orted saction(Ownershi Form: Direct (D) or Indirec (I) (Instr. 4	Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exercis	sable	Expiration Date	Title	Amount or Number of Shares					
Stock	\$10.41	06/15/2011			M			2,500	(5))	02/02/2015	Commor	2,500	\$0.00		6,800	D	

Explanation of Responses:

- 1. Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1.
- 2. Open market sales reported on this line occurred at a weighted average price of \$46.50 (range \$46.08 to \$46.96).
- 3. Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- 4. Open market sales reported on this line occurred at a weighted average price of \$47.14 (range \$47.00 to \$47.41).
- 5. Fully vested.

Remarks:

Valerie L. Andrews, Attorney-In-Fact

06/16/2011

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.